DUBLIN, April 28 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
For* Against Withheld** 1. To receive the Company's accounts together with the director's and auditor's reports 385,589,148 2,271,000 26,380 2. To approve the Remuneration Report 307,647,526 60,796,610 19,442,392 3. To elect Dr Barry Price as a Director of the Company 356,441,471 31,425,618 19,439 4. To re-appoint Deloitte LLP as Auditors of the Company 387,555,848 311,630 19,050 5. To authorize the Audit, Compliance and Risk Committee to determine the remuneration of the Auditors 387,180,598 671,746 34,184 6. To authorize the allotment of shares 332,997,412 54,868,377 20,739 7. To authorize the disapplication of pre-emption rights 387,558,665 297,124 30,739 8. To authorize market purchases 387,693,316 173,212 20,000
* These figures include discretionary votes
** A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution.
Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
Notes to Editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact: Shire plc: Tony Guthrie, Deputy Company Secretary, +44(0)1256-894746 Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-617-551-9715 Media Jessica Mann (Rest of the World) +44-1256-894-280 Matthew Cabrey (North America) +1-484-595-8248 Jessica Cotrone (North America) +1-617-613-4640
For further information please contact: Shire plc: Tony Guthrie, Deputy Company Secretary, +44(0)1256-894746. Investor Relations: Clea Rosenfeld (Rest of the World), +44-1256-894-160; Eric Rojas (North America), +1-617-551-9715. Media: Jessica Mann (Rest of the World), +44-1256-894-280; Matthew Cabrey (North America), +1-484-595-8248; Jessica Cotrone (North America), +1-617-613-4640